Corebridge Financial
CRBG
$29.18
-0.55%
Corebridge Financial, Inc. is a major provider of retirement solutions and insurance products in the United States, operating within the asset management and insurance industry. The company is a significant player in the annuities and retirement plan market, offering fixed, fixed index, and registered index-linked annuities distributed through an extensive platform. The current investor narrative is heavily influenced by the stock's volatile performance and its sensitivity to interest rates and capital market fluctuations, as evidenced by its sharp price decline in early 2026 followed by a partial recovery, with ongoing debate centered on its path to consistent profitability and the execution of its strategic initiatives post-spinoff from AIG.…
CRBG
Corebridge Financial
$29.18
Investment Opinion: Should I buy CRBG Today?
Rating: Hold. The core thesis is that CRBG presents a high-risk, high-potential-reward opportunity where the compelling forward valuation is counterbalanced by severe fundamental instability, recommending a wait-and-see approach until earnings consistency is demonstrated.
Supporting Evidence: The bullish argument is anchored by a forward P/E of just 4.93x, implying massive upside if the analyst consensus EPS of $7.88 is achieved. This is supported by robust free cash flow generation of $2.02B TTM and a strong balance sheet with a current ratio of 2.84. Furthermore, the stock trades at a significant discount to its own historical valuation, with a PS ratio of 5.63 near the low end of its observed range. However, these positives are starkly contrasted by a trailing net margin of -12.67%, an ROE of -2.77%, and a 1-year price decline of -12.99% versus a strong market.
Risks & Conditions: The two biggest risks are 1) the recurrence of large quarterly losses that invalidate the forward earnings forecast, and 2) a sustained breakdown below the $22.19 support level, signaling a resumption of the primary downtrend. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of stable, positive net income, confirming the earnings recovery and potentially compressing the forward P/E further. It would downgrade to a Sell if quarterly net income turns negative again or if the stock breaks below $22 on sustained volume. Relative to its own history, the stock appears undervalued, but relative to its current unstable fundamentals, it is fairly valued, reflecting the substantial execution risk.
Sign up to view all
CRBG 12-Month Price Forecast
CRBG is a classic 'show me' story trading on the promise of normalized earnings. The valuation is compelling if the $7.88 EPS materializes, but the path is fraught with volatility, as evidenced by wild quarterly swings from large profit to loss. The recent price recovery suggests the market is giving management the benefit of the doubt, but confidence is fragile. The stance is neutral due to the high degree of binary outcome risk; the stock could work higher in a grind or collapse if earnings disappoint. The rating would upgrade to bullish on confirmation of two consecutive quarters of stable profitability. It would turn bearish on a breakdown below $22.19 or a return to significant quarterly losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corebridge Financial's 12-month outlook, with a consensus price target around $37.93 and implied upside of +30.0% versus the current price.
Average Target
$37.93
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$23 - $38
Analyst target range
Analyst coverage for CRBG is limited but active, with 5 analysts providing estimates. The consensus leans bullish, as evidenced by recent institutional ratings from firms like Barclays, Wells Fargo, and TD Cowen maintaining 'Overweight' or 'Buy' ratings. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $7.88 for the coming year, which, against the current price, implies a forward P/E of 4.93x. The target range for EPS is wide, from a low of $7.47 to a high of $8.40, signaling some uncertainty around the earnings recovery trajectory. The pattern in institutional ratings shows stability, with no downgrades in the recent data; all actions are reiterations of existing positive or neutral ratings. This suggests analyst conviction in the company's medium-term outlook despite recent volatility. The wide EPS target spread of nearly $1.00, or about 12% of the average, indicates differing views on the pace of the earnings normalization, which is a key driver of the investment thesis.
Bulls vs Bears: CRBG Investment Factors
The bull and bear cases for CRBG are sharply divided, with the bear side currently presenting stronger evidence due to the company's profound earnings volatility and significant year-long underperformance. The bull thesis hinges almost entirely on a successful earnings normalization priced at a deeply discounted forward P/E of 4.93x, supported by strong analyst forecasts and robust cash flow. The bear thesis is grounded in the harsh reality of extreme quarterly profit swings, a negative trailing ROE, and a stock price that has already experienced a near-40% drawdown. The single most important tension in the investment debate is the resolution of earnings volatility. If Corebridge can deliver consistent, positive net income in line with the $7.88 EPS forecast, the stock's deep value will be unlocked. If quarterly losses persist or recur, the low forward multiple will prove to be a value trap, and the stock could retest its recent lows.
Bullish
- Strong Free Cash Flow Generation: The company generated $2.02 billion in trailing twelve-month free cash flow, providing significant financial flexibility. This robust cash generation supports shareholder returns, as evidenced by $1.11 billion in stock repurchases, and funds strategic initiatives without heavy reliance on external capital.
- Extremely Low Forward P/E Valuation: The stock trades at a forward P/E of just 4.93x based on analyst consensus EPS of $7.88, indicating deep undervaluation if earnings materialize. This valuation is a fraction of the negative trailing P/E (-44.46), reflecting market skepticism but offering substantial upside if profitability normalizes as expected.
- Analyst Consensus Remains Bullish: Despite recent volatility, institutional analysts from Barclays, Wells Fargo, and TD Cowen maintain 'Overweight' or 'Buy' ratings, signaling professional conviction in a recovery. The average EPS forecast of $7.88 implies a clear path to profitability, with a high estimate of $8.40 suggesting significant potential earnings power.
- Stable Revenue and High Gross Margins: Quarterly revenue has been stable, ranging from $628M to $737M over the last eight quarters, with Q4 2025 showing 1.98% YoY growth. The business model supports a consistently high gross margin of 81.67%, typical of a fee-based insurance platform, indicating a fundamentally sound underlying operation.
Bearish
- Extreme Earnings Volatility and Losses: Profitability is highly inconsistent, with net income swinging from a $814M profit in Q4 2025 to a -$664M loss in Q1 2025, resulting in a trailing net margin of -12.67%. This volatility, driven by large 'other expenses' related to investments, makes forecasting difficult and undermines investor confidence in sustainable earnings.
- Valuation Metrics Signal Fundamental Stress: Key valuation ratios paint a troubled picture: a trailing P/E of -44.46, an EV/EBITDA of 47.14, and a negative ROE of -2.77%. The elevated EV/EBITDA suggests the market is valuing future earnings that are not yet reflected in current cash flows, creating vulnerability if the recovery is delayed.
- Severe Price Decline and High Volatility: The stock has suffered a 37.95% maximum drawdown from its 52-week high and is down 12.99% over the past year, significantly underperforming the SPY's +22.86% return. With a beta of 1.069, the stock is 7% more volatile than the market, amplifying downside risk during periods of stress.
- High Short Interest and Skepticism: A short ratio of 2.36 indicates significant market skepticism and betting against the stock's recovery. This overhang can pressure the stock price and slow any rally, as short sellers may aggressively defend their positions on any signs of weakness.
CRBG Technical Analysis
The prevailing price trend for CRBG is a pronounced downtrend with a significant recovery attempt. The stock has declined 12.99% over the past year, but this masks a dramatic 37.95% maximum drawdown from its 52-week high of $36.57 to its low of $22.19. Currently trading at $28.74, the price sits at approximately 50% of its 52-week range, indicating it is in a middle-ground position after a severe correction, suggesting a potential stabilization phase but not yet signaling a clear value opportunity or momentum play. Recent short-term momentum shows a strong recovery, with the stock up 22.35% over the last three months and 8.70% over the past month, sharply diverging from the negative one-year trend. This positive divergence suggests a potential trend reversal or a significant relief rally, especially notable given the stock's 1-month relative strength of +8.78 against the SPY's -0.08% return. Key technical levels are clearly defined by the 52-week low of $22.19 and high of $36.57. A sustained breakout above the recent recovery highs near $31 could signal a move toward testing the 52-week high, while a breakdown below the March low of $22.19 would confirm the resumption of the primary downtrend. The stock's beta of 1.069 indicates it is approximately 7% more volatile than the broader market, which is a critical consideration for risk management given its recent price swings.
Beta
1.07
1.07x market volatility
Max Drawdown
-38.0%
Largest decline past year
52-Week Range
$22-$37
Price range past year
Annual Return
-10.4%
Cumulative gain past year
| Period | CRBG Return | S&P 500 |
|---|---|---|
| 1m | +9.3% | +1.8% |
| 3m | +25.9% | +15.1% |
| 6m | -5.0% | +9.7% |
| 1y | -10.4% | +25.0% |
| ytd | -3.9% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRBG Fundamental Analysis
Corebridge's revenue trajectory shows stability but masks extreme volatility in profitability. Quarterly revenue for Q4 2025 was $720 million, representing a modest year-over-year growth of 1.98%. However, revenue has fluctuated between $628 million and $737 million over the last eight quarters, indicating a relatively stable top line. The growth story is not about acceleration but about the extreme swings in bottom-line results driven by investment gains and losses. Profitability is highly inconsistent, as evidenced by a net income of $814 million in Q4 2025 swinging from a net loss of -$664 million in Q1 2025. The gross margin remains high at 81.67%, typical for an insurance-based fee business, but the net margin is deeply negative at -12.67% on a trailing basis, highlighting the impact of volatile 'other expenses' on the income statement. The company has shown an ability to generate substantial cash flow, with trailing twelve-month free cash flow of $2.02 billion. The balance sheet appears manageable with a debt-to-equity ratio of 0.83, indicating moderate leverage. Financial health is supported by a strong current ratio of 2.84 and a return on equity of -2.77%, the latter underscoring the profitability challenges. The substantial FCF provides internal funding for growth and shareholder returns, such as the $1.11 billion in stock repurchases noted in the Q4 2025 cash flow statement.
Quarterly Revenue
$720000000.0B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRBG Overvalued?
Given the trailing twelve-month net income is negative, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 5.63, while the forward-looking valuation is better assessed via the forward P/E of 4.93, which implies the market expects a return to profitability. The significant gap between the negative trailing P/E of -44.46 and the low forward P/E of 4.93 highlights the market's expectation of a sharp earnings recovery in the coming year. Peer comparison is challenging due to missing industry average data in the provided valuation set. However, the stock's EV/EBITDA of 47.14 appears elevated, suggesting the market may be valuing future normalized earnings rather than current depressed results. The EV/Sales ratio of 1.40 provides a cleaner cross-sectional comparison point for capital-light financial firms. Historically, the stock's own valuation has compressed significantly. The current PS ratio of 5.63 is near the lower end of its historical range observed in the data, which has seen PS ratios as high as 33.68. This suggests the stock is trading at a discount to its own history, which could indicate a value opportunity if fundamentals stabilize, or it may reflect a market pricing in sustained fundamental deterioration.
PE
-44.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
47.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Corebridge's primary risk is extreme earnings volatility, as net income has swung from a $814M profit to a -$664M loss within a single year, driven by large, unpredictable 'other expenses' (e.g., -$861M in Q4 2025). This makes the business fundamentally unpredictable and challenges valuation. While the company generates strong free cash flow ($2.02B TTM) and maintains a manageable debt-to-equity ratio of 0.83, its return on equity is negative (-2.77%), indicating it is destroying shareholder capital on a trailing basis. Revenue concentration in North American retirement and insurance products also exposes it to regional economic and regulatory shifts.
Market & Competitive Risks: The stock trades at a significant discount to its own historical valuation, with a PS ratio of 5.63 versus past highs above 33, but this compression may reflect a permanent de-rating rather than a temporary opportunity. The elevated EV/EBITDA of 47.14 suggests the market is pricing in a future recovery that may not materialize. Competitively, the annuity and retirement plan market is mature and highly competitive, pressuring fee structures. The stock's beta of 1.069 indicates it is more volatile than the market, and its severe underperformance versus the SPY (-35.85% on a 1-year relative strength basis) highlights its sensitivity to interest rates and risk-off sentiment.
Worst-Case Scenario: The worst-case scenario involves a failure to stabilize earnings, leading to another quarter of significant net losses, which would shatter analyst confidence in the forward EPS estimates of ~$7.88. This could trigger a wave of downgrades and a re-rating to a distressed valuation. Combined with a broader market downturn or rising interest rates that pressure its investment portfolio, the stock could break below its recent 52-week low of $22.19. A realistic downside from the current price of $28.74 would be a retest and breach of that low, representing a potential loss of approximately -23%. In an extreme scenario where the earnings recovery is abandoned, the stock could fall toward book value, implying further downside.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company's net income has swung wildly from a $814M profit to a -$664M loss, driven by large 'other expenses'. This makes the business unpredictable. 2) Valuation Compression Risk: If the expected earnings recovery fails, the low forward P/E will expand, and the stock could re-rate lower. 3) Macro and Interest Rate Risk: As an annuity provider, its investment income and product demand are highly sensitive to capital market and interest rate fluctuations, contributing to its high beta of 1.069. 4) Technical Risk: The stock has already experienced a 37.95% drawdown and remains in a volatile downtrend, with potential to retest the $22.19 low.
The 12-month forecast for CRBG is bifurcated, with a base case target range of $30-$35 (50% probability), a bull case of $36-$40 (30% probability), and a bear case of $20-$24 (20% probability). The base case, which is most likely, assumes the company meets the analyst consensus EPS estimate of $7.88, leading to a gradual re-rating from the current depressed price. The key assumption is that quarterly earnings volatility subsides. The bull case requires consistent profits at the high end of estimates ($8.40 EPS), while the bear case is triggered by a return to significant quarterly losses, breaking key technical support.
CRBG sends mixed valuation signals, making it situationally undervalued. On a forward-looking basis, it appears deeply undervalued with a forward P/E of 4.93x. However, trailing metrics tell a different story: a negative trailing P/E of -44.46 and an elevated EV/EBITDA of 47.14 reflect current fundamental stress. The Price-to-Sales ratio of 5.63 is near the low end of its historical range, suggesting a discount to its own history. The market is effectively valuing the stock on expected future earnings, implying it is fairly valued given the high execution risk, but undervalued if those earnings are delivered.
CRBG is a high-risk, high-potential-reward stock that may be a good buy only for investors with a high risk tolerance and a conviction in the company's earnings turnaround. The forward P/E of 4.93x based on a $7.88 EPS estimate is deeply discounted and offers substantial upside if achieved. However, the trailing fundamentals are poor, with a negative ROE and extreme quarterly earnings volatility. The 37.95% maximum drawdown and high short interest (ratio 2.36) underscore the risk. It is not a good buy for conservative investors but could be a tactical holding for those betting on a successful normalization of profits.
CRBG is primarily suitable for a medium- to long-term investment horizon (12-24 months minimum) for investors betting on the earnings turnaround thesis. The stock's high volatility (beta 1.069) and lack of a meaningful dividend (yield 3.14%) make it a poor candidate for short-term trading or income. The investment thesis hinges on the execution of a multi-quarter plan to stabilize profitability, which cannot be assessed in a short time frame. Given the binary outcome risk, a long-term hold allows time for the thesis to play out, but investors must be prepared for significant price swings along the way.